β細胞模擬設計細胞は,閉ループの血糖制御を提供します
Mingqi Xie1, Haifeng Ye2, Hui Wang1
1Department of Biosystems Science and Engineering, ETH Zurich, Mattenstrasse 26, CH-4058 Basel, Switzerland.
まとめ
研究 者 たち は,人 の 細胞 を "設計 者 の 細胞"に 変え て,胰臓 の ベータ 細胞 を 模倣 し まし た. この細胞はネズミの血糖値を効果的に管理し,糖尿病の新たな治療法となる可能性がある.
科学分野:
- バイオテクノロジー
- 内分泌学
- 合成生物学
背景:
- 糖尿病は,ベータ細胞喪失 (T1D) またはインスリン感受性および放出 (T2D) の障害による慢性的な血糖値低下を伴う.
- 現在の治療法では 長期的な血糖コントロールと合併症に 苦しんでいます
研究 の 目的:
- 最小限のヒト細胞工学を用いて 治療的に適用可能な 血糖反応性"設計細胞"を開発する.
- 1型と2型糖尿病の治療のための合成生物学的システムを確立する.
主な方法:
- 合成回路で合成したヒト細胞が 甘解媒介によるカルシウム吸収を 刺激-転写システムに結合する.
- 治療用トランスゲン発現が 血糖値に反応する
- 1型と2型糖尿病のマウスモデルに 組み立てられた細胞を埋め込みました
主要な成果:
- 1型糖尿病のマウスのインスリン欠乏症と高血糖症を正常化させた.
- 2型糖尿病のマウスでは,グルカゴン型ペプチド1を発現する遺伝子組み換え細胞によって,グルコース耐性およびインスリン放出が改善されました.
- 自給自足のグルコース調節と治療用トランスゲン発現が実証されています.
結論:
- 人間の細胞の最小限の工学は 機能的なベータ細胞模倣設計細胞を作り出すことができます
- 合成生物回路は糖尿病治療の有効な戦略です
- これらのシステムは糖尿病の併用診断と治療の 可能性を秘めています
関連する概念動画
Insulin: Biosynthesis, Chemistry, and Preparation
1.7K
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
1.7K
Glucagon-like Receptor Agonists
1.1K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.1K
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
2.9K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
2.9K
Oral Hypoglycemic Agents: Glinides
789
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
789
Hypoglycemia and Glucagon
1.1K
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
1.1K
Feedback Loops
67.1K
In most cases, excessive hormone production is prevented by negative feedback—a loop that starts with a stimulus inducing the release of a particular substance, like a hormone, to maintain a certain level before triggering a signal that results in a decrease in further release of the hormone.
67.1K


